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Received February 4, 2014; accepted May 31, 2014AbstractBackground: The herb pair of Salvia miltiorrhiza and Panax notoginseng has widely been used for improving coronary and cerebral circulation
in China. However, the exact contribution of the major active components of S. miltiorrhiza and P. notoginseng to cardioprotection is far from
clear. In the present study, three representative ingredients, salvianolic acid B (SalB) from S. miltiorrhiza and ginsenoside Rg1 (Rg1) and
ginsenoside Rb1 (Rb1) from P. notoginseng, were selected to elucidate the mechanism of the herb pair at the ingredient level.
Methods: The purity of SalB, Rg1, and Rb1 was >99%, as detected by high-performance liquid chromatography. Acute myocardial infarction
was introduced by ligation of the left anterior descending coronary artery near the main pulmonary artery. Cardiac contractility was detected
through a Mikro-tipped catheter, and cardiac infarct size was determined using triphenyltetrazolium chloride stain.
Results: The combination of SalB and Rg1, and not the combination of SalB and Rb1, improved heart contractility in rats with myocardial
infarction. The different contributions of Rg1 and Rb1, in combination with SalB, to cardioprotection provides further direction to optimize and
modernize the herbal medicines containing S. miltiorrhiza and P. notoginseng.
Conclusion: The combination of SalB and Rg1 may provide potential protection against myocardial infarction.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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The herb pair that is the focus of our investigation, derived
from the roots of Salvia miltiorrhiza (Danshen in Chinese) and
Panax notoginseng (Sanqi in Chinese), has been used widely for
improving coronary or cerebral circulation in China as well as inConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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http://dx.doi.org/10.1016/j.jcma.2014.10.001
1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical AssWestern countries.1 Many kinds of commercially available
preparations including this herb pair, known as Fufang Danshen
formulae, have beenmarketed for a long time and are considered
first-line drugs among all traditional Chinese medicines.2
However, the detailed mechanism of the combination of
S. miltiorrhiza and P. notoginseng has never been thoroughly
elucidated. Active components in these two ingredients possess
both the characteristic of complex formulae and the feature of
simplicity to facilitate research. Therefore, study of the active
components is the necessary foundation and a requisite cut-point
for the full investigation of general herb pairs.3
Danqi tablet, a famous traditional recipe containing
S. miltiorrhiza and P. notoginseng, has been officially recordedociation. All rights reserved.
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nary and cerebral circulation.4 More than 100 compounds have
been isolated and identified in S. miltiorrhiza and P. noto-
ginseng to date,5,6 but only a fraction of these compounds
were confirmed to be responsible for their biological effects.7,8
Salvianolic acid B (SalB) from S. miltiorrhiza, accompanied
by ginsenoside Rg1 (Rg1) and ginsenoside Rb1 (Rb1) from
P. notoginseng, have been used as phytochemical markers for
the quality control of Danqi tablet.9 SalB was reported to have
antioxidant, anti-arteriosclerotic, and anti-inflammatory ef-
fects, and to prevent angina pectoris and myocardial
ischemia.10,11 Rb1 exhibits a sedative effect on the central
nervous system, as well as anti-inflammation and vasodilation.
Rg1 possesses antifatigue properties and also excites the
central nervous system. SalB, Rg1, and Rb1 have been proved
to be bioactive for the prevention and treatment of cardio-
vascular and cerebrovascular diseases.12,13
Recently, high performance liquid chromatography coupled
with diode array and evaporative light scattering detectors
(HPLCeDADeELSD) method was successfully applied to
the simultaneous quantification of multicomponents in Danqi
tablet.14 Among the four major phenolic acids of S. miltior-
rhiza, SalB accounts for 76.2%. Among the four major sa-
ponins of P. notoginseng, Rg1 accounts for 40.5% and Rb1 for
40.0%. It is unquestionable that the most abundant compo-
nents among Danqi tablet are SalB (8.26 mg/g), Rg1
(15.15 mg/kg), and Rb1 (12.63 mg/kg).
To elucidate the mechanism involved in the combination of
S. miltiorrhiza and P. notoginseng at the active components
level, we evaluate the cardioprotection of SalB in combination
with Rg1 and in combination with Rb1 separately.
2. Methods2.1. Purity detection of SalB, Rg1, and Rb1SalB, Rg1, andRb1were purchased fromShanghaiYousi Bio-
Tech Co., Ltd. (Shanghai, China). The purity of these compounds
was analyzed by HPLC. Briefly, SalB, Rg1, or Rb1 solution was
filtered through a 0.45 mm membrane and injected into the Agi-
lent 1100 HPLC system (Agilent Technologies, Palo Alto, CA,
USA). The column configuration consisted of a Zorbax Extend
SB-C18 column (5 mm, 250mm 4.6 mm). The sample injection
volume was 10 mL. The detection wavelength was set at 280 nm
for SalB and Rg1, and at 203 nm for Rb1. The mobile phase for
SalB or Rg1 consisted of acetonitrile (A) and 0.05% aqueous
trifluoroacetic acid (V/V) (B), using a gradient elution of 2e10%
A at 0e7 minutes, 10e30% A at 7e20 minutes, 23e27% A at
20e35 minutes, and 27e60% A at 35e50 minutes. The mobile
phase for Rb1 consisted of acetonitrile (A) and 0.03% aqueous
phosphoric acid (V/V) (B), using an isocratic elution of 30% A.2.2. Preparation of rats with acute myocardial infarction
and their treatment with compoundsFig. 1. Experimental design. Compounds or combination of compounds was
given twice through intragastric administration during the whole experiment.
Rb1 ¼ ginsenoside Rb1; Rg1 ¼ ginsenoside Rg1; SalB ¼ salvianolic acid B;
TTC ¼ triphenyltetrazolium chloride.Wistar male rats (230e250 g) were purchased from the
Shanghai Center of Experimental Animals (Shanghai, China),part of the Chinese Academy of Sciences. Recommendations
from the “Guide for the Care and Use of Laboratory Animals”
published by the US National Institutes of Health were fol-
lowed throughout. All procedures involving animals were
approved by the Institutional Animal Care and Use Committee
at Shanghai Institute of Materia Medica (Shanghai, China;
IACUC number: SIMM-AE-GDA-2010-06). Acute myocar-
dial infarction (AMI) was introduced by ligation of the left
anterior descending coronary artery near the main pulmonary
artery. The sham operation was performed using an identical
procedure, except that the suture was passed under the coro-
nary artery without ligation.
Two sets of experiments were conducted to detect the
cardioprotective capacity of the combinations of SalB and
Rg1, and SalB and Rb1. The ratio of SalB to Rg1 (2:5) or that
of SalB to Rg1 (2:5) was set because the content of SalB was
8.26 mg/g, Rg1 was 15.15 mg/kg, and Rb1 was 12.63 mg/kg
in a Danqi tablet.14 The detailed protocol is shown in Fig. 1. A
compound or a combination of compounds (60 mg/kg) was
given twice through intragastric administration during the
entire experiment. The first compound was administered at
1 hour after surgery, and the second treatment was initiated
1 hour before sampling.
To detect the cardioprotective capacity of the combination
of SalB and Rg1, animals were randomly assigned into five
groups: sham-operated rats were given saline (Sham), AMI
rats were given saline (AMI), AMI rats were given 60 mg/kg
SalB (SalB), AMI rats were given 60 mg/kg Rg1 (Rg1), and
AMI rats were given 60 mg/kg SalB plus Rg1 (SalBeRg1, and
the ratio of SalB to Rg1 was 2:5).
To detect the cardioprotection of the combination of SalB
and Rb1, animals were also randomly assigned into five
groups: sham-operated rats were given saline (Sham), AMI
rats were given saline (AMI), AMI rats were given 60 mg/kg
SalB (SalB), AMI rats were given 60 mg/kg Rb1 (Rb1), and
AMI rats were given 60 mg/kg SalB plus Rb1 (SalBeRb1, the
ratio of SalB to Rb1 was 2:5).
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intragastric administration, the rats were anesthetized with
choral hydrate (335 mg/kg). A Mikro-tipped SPR-320 catheter
(Millar Instruments Inc., Houston, TX, USA) was inserted
through the right carotid artery and into the left ventricle. The
heart rate, mean arterial pressure, and left ventricular systolic
pressure (LVSP) of rats were recorded by a PowerLab 8/30
instrument (ADInstruments, Bella Vista, NSW, Australia),
where the maximum rate of pressure development (þdP/dtmax)
and the maximum rate of relaxation (dP/dtmin) were all
derived or calculated from the continuously obtained pressure
signal. All the parameters were analyzed using Chart 5 Pro
software (ADInstruments).2.4. Infarct size determination on the left ventricleAfter measurement of hemodynamic parameters, the rats
were sacrificed and their hearts were quickly excised. The left
ventricle was sliced into six 1.2e1.5-mm-thick sections
perpendicular to the long axis of the heart. The sections were
then incubated in phosphate buffered saline containing 0.1%
triphenyltetrazolium chloride (TTC) at 37C for 15 minutes.
Thereafter, the weights of the TTC-stained area, and the TTC-
negative stained area were measured. Myocardial infarct size
was expressed as a percentage of the infarct part (TTC-negative
stain) to the whole heart (TTC-stain plus TTC-negative stain).2.5. Statistical analysisAll quantitative values were expressed as mean ± standard
error and analyzed by SPSS 18.0 software (SPSS Inc., Chi-
cago, IL, USA). The mean values of the data from different
groups were compared using a one-way analysis of variance.
After confirming the equal variances, the least-significant
difference was used to compare the differences between theFig. 2. Structure and purity of SalB, Rg1, and Rb1. Chemical structures of (A) SalB
Rg1, and (F) Rb1. The purity of every compound was >99%. HPLC ¼ high-perform
SalB ¼ salvianolic acid B.two groups. A p value of <0.05 was considered to be statis-
tically significant.
3. Results3.1. Purity of SalB, Rg1, and Rb1Four types of phenolic acids from S. miltiorrhizae were
identified based on the number of benzene rings in their
structure. SalB is a tetramer, and its chemical structure is
shown in Fig. 2A. Rg1 is a 20 (S)-protopanaxatriol saponin,
while Rb1 is a 20 (S)-protopanaxadiol saponin. The chemical
structures of Rg1 and Rb1 are shown in Fig. 2B and C,
respectively. The purity of SalB, Rg1, and Rb1 was evaluated
by HPLC, and the purity of SalB was 99.8% (Fig. 2D), Rg1
was 99.8% (Fig. 2E), and Rb1 was 99.6% (Fig. 2F).3.2. Neither the combination of SalB and Rg1, nor the
combination of SalB and Rb1 decreased infarct size in
ratsTo determine the protective effect of SalBeRg1 or
SalBeRb1 on myocardial injury in our system, we dissected rat
hearts and stained them with TTC to evaluate the infarct size.
The representative TTC stain for SalBeRg1 is shown in
Fig. 3A, and the quantitative data of infarct size are given in
Fig. 3B. Ligation of the left anterior descending coronary artery
induced a significant increase in infarct size in the AMI group
(17.73 ± 3.22%) compared with the Sham group ( p < 0.001),
whereas 60 mg/kg SalB (14.43 ± 4.61%), 60 mg/kg Rg1
(18.11 ± 7.10%), and 60 mg/kg SalBeRg1 (17.14 ± 6.08%)
did not attenuate the infarct size compared with the AMI group.
The representative TTC stain for SalBeRb1 is shown in
Fig. 3C, and the quantitative data of infarct size are presented
in Fig. 3D. Ligation of the left anterior descending coronary
artery induced a significant increase in infarct size in the AMI
group (22.31 ± 5.65%) compared with the Sham group, (B) Rg1, and (C) Rb1. Representative HPLC chromatograms of (D) SalB, (E)
ance liquid chromatography; Rb1 ¼ ginsenoside Rb1; Rg1 ¼ ginsenoside Rg1;
Fig. 3. Neither the combination of SalB and Rg1, nor the combination of SalB and Rb1 decreased infarct size in rats. Representative photographs of TTC stain for
combination of (A) SalB and Rg1, and (C) SalB and Rb1. (B) Quantitative results for TTC stain for combination of SalB and Rg1, and (D) SalB and Rb1. All the
values are expressed as mean ± SE; n ¼ 10 for each group. ***p < 0.001 versus Sham rats. AMI ¼ acute myocardial infarction; Rb1 ¼ ginsenoside Rb1;
Rg1 ¼ ginsenoside Rg1; SalB ¼ salvianolic acid B; SE ¼ standard error; TTC ¼ triphenyltetrazolium chloride.
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kg Rb1 (16.83 ± 4.9%), and 60 mg/kg SalBeRb1
(23.17 ± 6.74%) did not attenuate the infarct size compared
with the AMI group.3.3. Combination of SalB and Rg1 improved left
ventricle contractilityThe major hemodynamic parameters were measured to
evaluate the left ventricle contractility after treatment with
SalBeRg1 (Fig. 4). No influence of SalB, Rg1, and SalBeRg1
was found on the mean pressure and heart rate. The left
ventricle dysfunction was confirmed in the AMI rats, compared
with the Sham group, with a significant decrease of þdP/dtmax
(6371.1 ± 1174.2 mmHg/s vs. 8831.2 ± 1697.4 mmHg/s,
p < 0.01), dP/dtmin (5247.9 ± 1266.5 mmHg/s vs.
8489.8 ± 2866.3 mmHg/s, p < 0.01), and LVSP
(91.0 ± 8.7 mmHg vs. 103.4 ± 8.9 mmHg, p < 0.05), and an
increase of end-diastolic pressure (EDP; 9.0 ± 5.7 mmHg vs.
0.6 ± 3.2 mmHg, p < 0.01). SalBeRg1 treatment partially
reversed the impairment of left ventricle function by
improving þ dP/dtmax (8149.86 ± 1066.11 mmHg/s vs.
6371.06 ± 1174.17 mmHg/s, p < 0.01) compared with the AMI
group. No significant improvement was found in cardiaccontractility by SalBeRg1 treatment, based on the LVSP, þdP/
dtmax, dP/dtmin, and EDP values.3.4. Combination of SalB and Rb1 did not improve left
ventricle contractilityThe major hemodynamic parameters were measured to
evaluate the left ventricle contractility after treatment with
SalBeRb1 (Fig. 5). No influence of SalB and SalBeRb1 was
found on the mean pressure and heart rate. The left ventricle
dysfunction in the AMI rats was confirmed, compared with the
Sham group, with a significant decrease of LVSP
(101.9 ± 11.7 mmHg vs. 119.9 ± 17.3 mmHg, p < 0.05), þdP/
dtmax (6354.9 ± 1414.9 mmHg/s vs. 9653.7 ± 2505.9 mmHg/s,
p < 0.01), and dP/dtmin (5063.4 ± 1914.9 mmHg/s vs.
8432.2 ± 1339.9 mmHg/s, p < 0.01), and an increase of EDP
(9.7 ± 3.9 mmHg vs. 5.2 ± 3.4 mmHg, p < 0.05). No signif-
icant improvement was found on cardiac contractility by SalB,
Rb1, or SalBeRb1 treatment, comparing with the AMI group.
4. Discussion
The present study unraveled the different effects of Rg1 and
Rb1, in combination with SalB, on cardiac protection in vivo.
Fig. 4. Combination of SalB and Rg1 improved cardiac function of AMI rats. All the values are expressed as mean ± SE; n ¼ 10 for each group. *p < 0.05 versus
Sham. **p < 0.01 versus Sham. ##p < 0.01 versus AMI. AMI ¼ acute myocardial infarction; þdP/dtmax ¼ maximum rate of pressure development for contraction;
dP/dtmin ¼ maximum rate of pressure development for relaxation; EDP ¼ end-diastolic pressure; LVSP ¼ left ventricular systolic pressure; Rb1 ¼ ginsenoside
Rb1; Rg1 ¼ ginsenoside Rg1; SalB ¼ salvianolic acid B; SE ¼ standard error.
118 Y. Deng et al. / Journal of the Chinese Medical Association 78 (2015) 114e120The combination of SalB and Rg1 showed significant
improvement in cardiac contractility in rats with myocardial
infarction, but not the combination of SalB and Rb1. This
emphasizes the need to understand the individual and collec-
tive actions of herbal ingredients and further elucidate the
therapeutic mechanism of the herbal pairs.
Although the efficacy-driven approach is now widely
applied in studies of this herb pair, the ultimate purpose of
investigation is to provide reasonable, secure, and effective
indications for pharmacy medication and prescription in actual
clinical practice.15 Studies on active ingredients and their
mechanisms are crucial for further development of herb pairs.
The most abundant and active component of S. miltiorrhiza is
SalB,16 while the most abundant and active components of
P. notoginseng are Rg1 and Rb1.17 Detecting the effects of
combinations of representative ingredients from S. miltior-
rhiza and P. notoginseng on cardioprotection, which is the
usual clinical indication, would provide further direction for
modernization of the traditional medicines containing this
herb pair.
Besides the chemical structure, differences between Rg1
and Rb1 in terms of bioactivity were also reported recently.18Angiogenesis in the human body is regulated by two sets of
counteracting factors, angiogenic stimulators and inhibitors.19
Rg1 promotes functional neovascularization into a polymer
scaffold in vivo and proliferation, chemoinvasion, and tubu-
logenesis of endothelial cells in vitro.20 By contrast, Rb1 ex-
erts an opposing effect and inhibits the earliest step in
angiogenesisdthe chemoinvasion of endothelial cells.21 In our
present study, the different effects of Rg1 and Rb1 in combi-
nation with SalB were observed on cardioprotection in vivo,
providing a new difference between the effects of Rg1 and
Rb1. Additionally, further research is very important to clarify
whether the difference between Rg1 and Rb1, in combination
with SalB, is related to the different effects of the two com-
pounds on angiogenesis or not.
Many ingredients of herbs are inactive individually but
become active in combinations, called coalist combinations,
which are common in herb pairs.22 In the present study, our
finding suggests that coalist actions exist between SalB and
Rg1. Rg1 is well known as a cosolvent, which can decrease the
surface tension of menstruum.23 Therefore, Rg1 may promote
the dissolution of SalB. Pharmacological research has indi-
cated that SalB focuses on expanding blood vessels, whereas
Fig. 5. Combination of SalB and Rb1 did not improve cardiac function of AMI rats. All the values are expressed as mean ± SE; n ¼ 10 for each group. *p < 0.05
versus Sham. **p < 0.01 versus Sham. ***p < 0.001 versus Sham. #p < 0.05 versus AMI. AMI ¼ acute myocardial infarction; þdP/dtmax ¼ maximum rate of
pressure development for contraction; dP/dtmin ¼ maximum rate of pressure development for relaxation; EDP ¼ end-diastolic pressure; LVSP ¼ left ventricular
systolic pressure; Rb1 ¼ ginsenoside Rb1; Rg1 ¼ ginsenoside Rg1; SalB ¼ salvianolic acid B; SE ¼ standard error.
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the present study, the improvement in cardiac contractility by
the combination of the two ingredients may be attributed to the
different protective mechanisms of SalB and Rg1.
In conclusion, a combination of SalB from S. miltiorrhiza
and Rg1 fromP. notoginseng exhibited significant improvement
on cardiac contractility in rats with myocardial infarction.
However, no improvement attributable to the combination of
SalB and Rb1 was observed in the same investigation, sug-
gesting different contributions of Rg1 and Rb1, in combination
with SalB, to cardioprotection. Elucidation of the exact roles of
the major components of S. miltiorrhiza and P. notoginseng
would promote the optimization and modernization of tradi-
tional medicines containing this herb pair.
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